Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

Autor: Jon Sponheim, Amalie Christine Poole, Hong-Thien Thi Nguyen, Espen Thiis-Evensen
Rok vydání: 2020
Předmět:
Male
Oncology
Cancer Research
Time Factors
medicine.medical_treatment
Neuroendocrine tumors
Octreotide
Peptide receptor radionuclide therapy
030218 nuclear medicine & medical imaging
Targeted therapy
Chemoteraphy
0302 clinical medicine
Surgical oncology
Antineoplastic Combined Chemotherapy Protocols
Stage (cooking)
Aged
80 and over
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Combined Modality Therapy
Primary tumor
Survival Rate
Neuroendocrine Tumors
030220 oncology & carcinogenesis
Disease Progression
Female
Fluorouracil
Radiology
Research Article
medicine.drug
Adult
medicine.medical_specialty
Receptors
Peptide
lcsh:RC254-282
Streptozocin
03 medical and health sciences
Neuroendocrine tumor
Internal medicine
Organometallic Compounds
Genetics
medicine
Humans
Everolimus
Aged
Retrospective Studies
Chemotherapy
business.industry
medicine.disease
Treatment
Radionuclide therapy
Radiopharmaceuticals
business
Follow-Up Studies
Zdroj: BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Cancer
ISSN: 1471-2407
DOI: 10.1186/s12885-020-06963-6
Popis: Background There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally, the aim of these treatments has been to reduce the tumor load; referred to as objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without a reduction in total tumor load; termed as stable disease (SD). We wanted to investigate whether achieving OR compared to obtaining SD predicted a longer time to progression (TTP) in patients with neuroendocrine tumors (WHO Grade 1 and 2) treated with peptide receptor radionuclide therapy, chemotherapy or molecular targeted therapy. Methods Patients treated with either peptide receptor radionuclide therapy (PRRT) with 177Lutetium-DOTA-octreotate, the chemotherapy combination streptozotocin/5-fluorouracil or everolimus were retrospectively assessed to evaluate the effect of the treatments on disease progression. We analyzed the TTP for patients for each treatment modality and compared the TTP between those who achieved OR and those who achieved SD. Results Altogether 56 patients treated with PRRT, 32 treated with streptozotocin/5-fluorouracil and 52 treated with everolimus were included in the analyses. The median TTP for those treated with PRRT and achieving OR was 31 months, the TTP for those achieving SD was 43 months (p = 0,2). For patients treated with streptozotocin/5-fluorouracil the results were: OR: 18 months, SD: 23 months (p = 0,9) and for those treated with everolimus; OR: 9 months, SD: 20 months (p = 0,5), respectively. We found no differences between patients achieving OR compared to SD regarding age, sex, stage, primary tumor location, Ki-67% or ongoing treatment with somatostatin analogues. Conclusions We found no treatment benefit with regard to TTP for our patients that experienced OR compared to those who achieved SD.
Databáze: OpenAIRE
Externí odkaz: